

# Symptomatology of COVID-19, rhinovirus and undifferentiated viral infections in a static military population

Ela Stachow <sup>1,2</sup>, S Warden,<sup>2</sup> K Cockcroft,<sup>2</sup> S Schofield<sup>2</sup>

Civilian and serving military populations have several broad demographic differences. These include a younger age, higher level of physical fitness and lower prevalence of comorbidities in the military group. Therefore, the symptomatology of COVID-19 in military patients may not directly correlate with that more widely published in civilian literature.<sup>1-3</sup>

We analysed a static population (n=91) of symptomatic military personnel presenting to a Royal Navy medical team during concurrent SARS-CoV-2 and rhinovirus outbreaks. All patients identified as suspected COVID-19 cases (as per Public Health England criteria)<sup>4</sup> were tested for SARS-CoV-2 using BioFire FilmArray PCR analysis. In some cases, a wider panel was used to test for multiple respiratory pathogens, which allowed for the detection of rhinovirus. The question of interest was whether there were symptoms within this military population which differentiated between the presence or absence of SARS-CoV-2.

Retrospective data collection was undertaken by reviewing the medical records of all symptomatic patients tested for SARS-CoV-2 in addition to those with a positive SARS-CoV-2 PCR result from tests taken during screening serials. The test result for each patient was noted alongside the documented symptomatology for their episode. Statistical significance of the difference between SARS-CoV-2-positive and SARS-CoV-2-negative test status for each symptom was determined using Fisher's exact test. A p value of <0.05 was deemed to signify statistical significance.

A total of 91 patients met the criteria outlined earlier. Of these, 12 were lost to follow-up, all as a result of moving to another primary care facility. Of the

remaining dataset, 21 patients tested positive for SARS-CoV-2 and 58 tested negative, 5 of which tested positive for rhinovirus. No patients tested positive for both SARS-CoV-2 and rhinovirus. A wide range of symptoms were described, all of which are detailed in Table 1. Two of those who tested positive for SARS-CoV-2 remained asymptomatic throughout (Table 1).

There was a statistically significant difference in SARS-CoV-2-positive or SARS-CoV-2-negative test status for those with the grouped symptoms of loss or change of sense of smell or taste and the symptom of shortness of breath (both more likely in SARS-CoV-2-positive cases) alongside sore throat (more likely in SARS-CoV-2-negative cases). The remainder of documented symptoms revealed no difference of statistical significance. Interestingly, this does not correlate

with civilian data in studies on younger adults, in which shortness of breath is described as uncommon.<sup>5</sup> The rhinovirus-positive cases were not analysed as a separate subgroup as not all symptomatic cases were tested for rhinovirus.

These results should be treated with caution on account of the format of data collection, which relied on reporting and documentation of symptoms, and the large number of symptoms included in the analysis which increased the risk of statistically significant findings arising by chance. The attrition rate from the study was unlikely to have been influenced by the patient's symptomatology, so this is an unlikely source of bias.

This study raises the notion that the presence of shortness of breath in military patients should increase a clinician's suspicion for COVID-19 in the context of the current pandemic. However, due to the limitations of the study, the presence of a sore throat should not be assumed to indicate that COVID-19 is not present.

**Contributors** ES conceived the project and conducted data collection and write-up. SW, KC and SS conducted the data collection.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Table 1** Symptoms documented for SARS-CoV-2 positive and negative patients alongside the P value relating to the difference derived using Fishers exact test.

Symptom	SARS-CoV-2 positive (n=21)	SARS-CoV-2 negative (n=58)	P value
Change/loss of taste/smell	13	8	<0.0001
Feeling febrile	7	21	1
Cough	15	52	0.07
Nasal congestion	2	8	1
Facial/sinus congestion	1	1	0.5
Rhinorrhoea	3	11	0.7
Sore throat	2	25	0.007
Headache	2	15	0.2
Fatigue	4	5	0.2
Wheeze	0	1	1
Chest tightness	1	3	1
Shortness of breath	7	5	0.01
Light-headedness	0	2	1
Muscle ache	2	3	0.6
Back pain	1	1	0.5
Night sweats	0	2	1
Photophobia	0	2	1
Swollen glands	0	1	1
Arthralgia	1	0	0.3
Nausea and vomiting	0	1	1

<sup>1</sup>Academic Department of Military General Practice, Research and Clinical Innovation, Royal Centre for Defence Medicine, Birmingham, UK

<sup>2</sup>Royal Navy Medical Service, Portsmouth, UK

**Correspondence to** Surg Lt Cdr Ela Stachow, Academic Department of Military General Practice, Research and Clinical Innovation, Royal Centre for Defence Medicine, Birmingham, UK; e.stachow@doctors.org.uk

**Ethics approval** This study was classified as a quality improvement project and therefore formal ethical approval was not deemed necessary. Internal registration of the project was undertaken with corresponding entries in patient medical records when access was gained for the purpose of the study. All data were anonymised.

**Provenance and peer review** Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Stachow E, Warden S, Cockcroft K, *et al.* *BMJ Mil Health* 2021;**167**:290–291.

Received 18 February 2021  
Revised 26 February 2021  
Accepted 9 March 2021  
Published Online First 19 March 2021

*BMJ Mil Health* 2021;**167**:290–291.  
doi:10.1136/bmj-military-2021-001819

#### ORCID iD

Ela Stachow <http://orcid.org/0000-0003-0201-6463>

#### REFERENCES

- 1 Alvarado GR, Pierson BC, Teemer ES, *et al.* Symptom characterization and outcomes of Sailors in isolation

after a COVID-19 outbreak on a US aircraft carrier. *JAMA Netw Open* 2020;3:2020981:e2020981. doi:10.1001/jamanetworkopen.2020.20981

- 2 Grant MC, Geoghegan L, Arbyn M, *et al.* The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. *PLoS One* 2020;15:234765. doi:10.1371/journal.pone.0234765
- 3 Nikolai LA, Meyer CG, Kreamsner PG, *et al.* Asymptomatic SARS coronavirus 2 infection: invisible yet invincible. *Int J Infect Dis* 2020;100:112–6. doi:10.1016/j.ijid.2020.08.076
- 4 The National Health Service. Symptoms of coronavirus [Internet], 2020. Available: <https://www.nhs.uk/conditions/coronavirus-covid-19/symptoms/>
- 5 Liao J, Fan S, Chen J, *et al.* Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. *Innovation* 2020;1:100001. doi:10.1016/j.xinn.2020.04.001